Bristol-Myers Squibb: 3 Key Takeaways for Long-Term Investors
Bristol-Myers Squibb reported strong Q3 2026 earnings with growth portfolio revenue up 12% to $7.7 billion and eight medicines now exceeding $1 billion in annualized sales. The company advanced four late-stage clinical trials and achieved FDA clearance for Symvexis. Despite a projected $1.5-2 billion revenue decline in 2027 from European patent expirations on Eliquis, management's cost discipline ($2 billion in savings), pipeline momentum, and internal manufacturing investments position the company for long-term resilience.
